TC
GILD icon

Trilogy Capital’s Gilead Sciences GILD Stock Holding History

Trilogy Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.18M Buy
41,026
+9,777
+31% +$1.29M 0.2% 86
2026
Q1 		$4.36M Buy
31,249
+1,546
+5% +$216K 0.19% 85
2025
Q4 		$3.65M Buy
29,703
+2,204
+8% +$268K 0.16% 101
2025
Q3 		$3.05M Sell
27,499
-48
-0.2% -$5.46K 0.14% 109
2025
Q2 		$3.05M Sell
27,547
-5,700
-17% -$607K 0.15% 100
2025
Q1 		$3.73M Sell
33,247
-4,060
-11% -$419K 0.2% 77
2024
Q4 		$3.45M Sell
37,307
-3,765
-9% -$339K 0.18% 87
2024
Q3 		$3.44M Sell
41,072
-235
-0.6% -$17.9K 0.17% 92
2024
Q2 		$2.83M Buy
41,307
+3,191
+8% +$213K 0.15% 105
2024
Q1 		$2.79M Buy
38,116
+33,202
+676% +$2.55M 0.16% 112
2023
Q4 		$398K Sell
4,914
-458
-9% -$35.6K 0.02% 190
2023
Q3 		$403K Sell
5,372
-419
-7% -$32.2K 0.03% 177
2023
Q2 		$467K Buy
5,791
+742
+15% +$59.2K 0.03% 176
2023
Q1 		$419K Sell
5,049
-23,304
-82% -$1.93M 0.03% 166
2022
Q4 		$2.43M Sell
28,353
-2,602
-8% -$206K 0.17% 78
2022
Q3 		$1.91M Buy
30,955
+3,632
+13% +$229K 0.17% 62
2022
Q2 		$1.69M Buy
27,323
+6,079
+29% +$376K 0.15% 61
2022
Q1 		$1.26M Buy
21,244
+4,284
+25% +$274K 0.09% 95
2021
Q4 		$1.23M Buy
16,960
+757
+5% +$52.1K 0.09% 81
2021
Q3 		$1.13M Buy
16,203
+19
+0.1% +$1.33K 0.09% 76
2021
Q2 		$1.1M Buy
16,184
+6,318
+64% +$422K 0.08% 78
2021
Q1 		$638K Buy
9,866
+741
+8% +$47.8K 0.05% 116
2020
Q4 		$532K Buy
9,125
+46
+0.5% +$2.78K 0.04% 113
2020
Q3 		$574K Sell
9,079
-360
-4% -$25K 0.05% 91
2020
Q2 		$737K Buy
9,439
+1,473
+18% +$113K 0.07% 71
2020
Q1 		$637K Buy
+7,966
New +$550K 0.07% 67
2019
Q1 		– Sell
-3,903
Closed -$244K – 135
2018
Q4 		$244K Sell
3,903
-3,427
-47% -$240K 0.03% 113
2018
Q3 		$566K Sell
7,330
-844
-10% -$63.7K 0.07% 90
2018
Q2 		$579K Sell
8,174
-468
-5% -$33K 0.08% 74
2018
Q1 		$652K Buy
+8,642
New +$687K 0.09% 69

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Trilogy Capital's GILD Position: Q2 2026 in Review

Trilogy Capital increased its Gilead Sciences (GILD) stake by 31% in Q2 2026, buying an estimated $1.29M and bringing the position to 41,026 shares worth $5.18M. The position accounts for 0.2% of the portfolio, ranked #86.

Trilogy Capital first reported a position in GILD in Q1 2018 and has held it in 30 quarters since. 361 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Trilogy Capital held 41,026 shares of Gilead Sciences worth $5.18M as of Q2 2026.
  • Trilogy Capital bought 9,777 Gilead Sciences shares in Q2 2026, an estimated $1.29M.
  • Gilead Sciences made up 0.2% of Trilogy Capital's portfolio in Q2 2026, its #86 holding.
  • Trilogy Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 30 quarters since.
  • 361 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.